CLAIMS

What is claimed is:

1. A therapeutic composition comprising at least one COX-2 selective inhibitor or a prodrug thereof and at least one LTB_4 receptor antagonist wherein the LTB_4 receptor antagonist comprises one or more compounds selected from the group consisting of 2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid; a pharmaceutically-acceptable salt thereof; and mixtures thereof.

2. The therapeutic composition of Claim 1, wherein the COX-2 selective inhibitor comprises celecoxib.

3. The therapeutic composition of Claim 1 wherein the LTB_4 receptor antagonist comprises 2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid.

4. The therapeutic composition of Claim 3 wherein the COX-2 selective inhibitor comprises celecoxib.

5. The therapeutic composition of Claim 1 wherein the LTB_4 receptor antagonist comprises a pharmaceutically-acceptable salt of 2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid.

6. The therapeutic composition of Claim 1 wherein the LTB_4 receptor antagonist comprises the mono(ethylene diamine) salt of 2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid.

7. The therapeutic composition of Claim 6 wherein the COX-2 selective inhibitor comprises celecoxib.

8. The composition of Claim 1 or 2, further comprising a pharmaceutically-acceptable excipient.

9. The composition of Claim 1 or 2, wherein the composition is a solid dosage form.

10. The composition of Claim 9, wherein the solid dosage form is an oral dosage form.

11. The composition of Claim 10, wherein the oral dosage form is selected from a group consisting of a tablet, a capsule, a suppository, a pill, a gel cap, and a granular composition.

12. The composition of Claim 11 wherein the oral dosage form is a capsule.

13. The composition of Claim 12 wherein the capsule is a time release capsule dosage form.

14. The composition of Claim 11 wherein the oral dosage form is a tablet dosage form.

15. The composition of 14 wherein the tablet dosage form is selected from a group consisting of a multiple layer tablet dosage form, a sustained release tablet dosage form, a core-mantle tablet dosage form, an osmotic tablet dosage form, and a side-by-side tablet dosage form.

16. The composition of Claim 15 wherein the tablet dosage form comprises a multiple layer tablet dosage form.

17. The therapeutic composition of Claim 15 wherein the tablet dosage form comprises a side-by-side tablet dosage form.

18. The composition of Claim 15 wherein the tablet dosage form comprises a sustained release tablet dosage form.

19. The composition of Claim 15 wherein the tablet dosage form comprises a core and mantle tablet dosage form.

20. The composition of Claim 1 or 2, wherein the COX-2 selective inhibitor or a prodrug thereof and an LTB_4 receptor antagonist are present in an intimate mixture.

21. The composition of Claim 1 or 2, wherein the composition is an aqueous form.

22. The composition of Claim 21, wherein the aqueous form is a syrup.

23. The composition of Claim 21, wherein the aqueous form is suitable for parenteral administration.

24. The composition of Claim 1 or 2, wherein the composition is in an inhalable dosage form.

25. The composition of Claim 1 or 2, wherein the composition is in a semi-solid dosage form.

26. The composition of Claim 25, wherein the semi-solid form is suitable for topical application.

27. The composition of Claim 1 or 2 wherein the composition is a suspension.

28. A method for the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain-related disorder, or pain in a subject in need of such prevention, treatment, or inhibition, the method comprising administering to the subject a composition comprising a COX-2 selective anti-inflammatory compound and an LTB_4 receptor antagonist compound, wherein the LTB_4 receptor antagonist compound comprises one or more compounds selected from the group consisting of 2-[(3S,4R)-3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid; salts; and mixtures thereof.

29. The method of Claim 28, wherein the COX-2 selective inhibitor comprises celecoxib.

30. The method of any one of Claims 28 or 29, wherein the subject is an animal.

31. The method of Claim 30, wherein the animal is a human.

32. The method of Claim 31 for the treatment, prevention or inhibition of an inflammation-related disorder.

33. The method of Claim 31 for the treatment, prevention or inhibition of inflammation.

34. The method of Claim 31 for the treatment, prevention or inhibition of pain.

35. The method of Claim 31 for the treatment, prevention or inhibition of a pain-related disorder.

36. The method of Claim 31 wherein the inflammation-related disorder is arthritis.

37. The method of Claim 36 wherein the arthritis is osteoarthritis.

38. The method of Claim 37 wherein the arthritis is rheumatoid arthritis.

39. The method of Claim 31, for the prevention or treatment of any one or more of the disorders selected from the group consisting of connective tissue and joint disorder, neoplasia disorder, cardiovascular disorder, otic disorder, ophthalmic disorder, respiratory disorder, gastrointestinal disorder, angiogenesis-related disorder, immunological disorders, allergic disorder, nutritional disorder, infectious disease and disorders, endocrine disorder, metabolic disorder, neurological and neurodegenerative disorder, psychiatric disorder, hepatic and biliary disorder, musculoskeletal disorder, genitourinary disorder, gynecologic and obstetric disorder, injury and trauma disorder, surgical disorder, dental and oral disorder, sexual dysfunction disorder, dermatologic disorder, hematological disorder, and poisoning disorder.

40. The method of claim 28 wherein the amount of LTB_4 receptor antagonist, and the amount of COX-2 selective inhibitor, are administered in a sequential manner.

41. The method of claim 28 wherein the amount of LTB_4 receptor antagonist and the amount of COX-2 selective inhibitor are administered in a substantially simultaneous manner.